PGPC3-75, SK1
SKi001-A
General
Cell Line |
|
| hPSCreg name | SKi001-A |
| Cite as: | SKi001-A |
| Alternative name(s) |
PGPC3-75, SK1
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines | No similar lines found. |
| Last update | 23rd October 2024 |
| User feedback | |
Provider |
|
| Generator |
Hospital for Sick Children (SK)
Contact:
Hospital for Sick Children (SK) |
| Owner | Hospital for Sick Children (SK) |
| Distributors | |
| Derivation country | Canada |
External Databases |
|
| BioSamples | SAMEA115579204 |
General Information |
|
| Publications |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
Donor Information
General Donor Information |
|
| Sex | male |
| Ethnicity | White |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
| Disease associated phenotypes | no phenotypes |
| Family history | https://personalgenomes.ca |
| Is the medical history available upon request? | https://personalgenomes.ca |
| Is clinical information available? | https://personalgenomes.ca |
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
No
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
Yes
|
External Databases (Donor) |
|
| BioSamples | SAMEA115579217 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
| If you do not hold the Donor Consent Form, do you know who does? | Yes |
| Please provide the contact information | jhowe@sickkids.ca |
| Alternatives to consent are available? | No |
| Is there other documentation provided to the donor for consenting purposes? | No |
| Confirm that consent was obtained by a qualified professional | Yes |
| Has the donor agreed to be re-contacted? | Yes |
| Has the donor been informed about how her/his data will be protected? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent expressly prevent the derivation of pluripotent stem cells? | No |
| Does consent pertain to a specific research project? | No |
| Does consent permit unforeseen future research, without further consent? | Yes |
| Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? | No |
| Does consent expressly prevent development of commercial products? | No |
| Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? | Yes |
| Does consent expressly permit storage of donated embryo/tissue for an unlimited time? | Yes |
| Does consent expressly permit storage of cells derived from the donated embryo/tissue for an unlimited time? | Yes |
| Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
| an academic institution? | Yes |
| a public organisation? | Yes |
| a non-profit company? | Yes |
| a for-profit corporation? | No |
| Does consent expressly permit collection of genetic information? | Yes |
| Does consent expressly permit storage of genetic information? | Yes |
| Does consent prevent dissemination of genetic information? | No |
| Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? | Yes |
| Has the donor consented to receive information discovered during use of donated embryo/tissue that has significant health implications for the donor? | Yes |
| How may genetic information associated with the cell line be accessed? | Open Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Does the consent anticipate that the donor will be notified of results or outcomes of any research involving the donated samples or derived cells? | No |
| Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? | No |
| Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? | No |
| Does consent permit access to medical records of the donor? | No |
| Does consent permit access to any other source of information about the clinical treatment or health of the donor? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Hospital for Sick Children Research Ethics Board |
| Approval number | 1000050639 |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
| Name of accrediting authority involved? | Hospital for Sick Children Research Ethics Board |
| Approval number | 1000050639 |
| Do you have obligations to third parties in regard to the use of the cell line? | No |
| Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? | No |
| Is there an MTA available for the cell line? | Yes |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | Invitrogen |
| Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | No |
hIPSC Derivation
General |
|
| Source cell type |
Hematopoietic progenitor cell antigen CD34 (385 aa, ~41 kDa) is encoded by the human CD34 gene. This protein plays a role in cell-cell adhesion and may have a role in leukocyte migration.
Synonyms
|
| Source cell origin |
A liquid tissue; its major function is to transport oxygen throughout the body. It also supplies the tissues with nutrients, removes waste products, and contains various components of the immune system defending the body against infection. Several hormones also travel in the blood.
Synonyms
|
| Source cell type (free text) | CD34 + cells from whole blood |
| Passage number reprogrammed | 1 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Is reprogramming vector detectable? |
Yes |
| Methods used |
RT-PCR
|
| Notes on reprogramming vector detection | Total RNA was isolated using TRIzol (Invitrogen). 1ug of RNA was used to generate cDNA with SuperScript VILO cDNA Synthethis kit (ThermoFisher). 10ul of the reaction was amplified with AccuPrime Tag DNA polymerase with Sendai primers. Resulting DNA was run on a 2% agarose gel. Passage 2 iPSC DNA samples were used as a positive control for the Sendai. |
| Files and images showing reprogramming vector expressed or silenced | |
Vector free reprogramming |
|
| Type of used vector free reprogramming factor(s) |
None
|
Other |
|
| Selection criteria for clones | Colonies were picked manually based on morphological IPS cell characteristics. |
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
Yes |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Matrigel/Geltrex | ||||||
| Feeder cells |
No |
||||||
| Passage method |
Enzymatically
ReLeSR (Stemcell Technologies) for iPS clumps and Accutase for single cell passage (Innovative Cell Technologies)
|
||||||
| O2 Concentration | 21 % | ||||||
| CO2 Concentration | 5 % | ||||||
| Medium |
mTeSR™ 1
Supplements
|
||||||
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | No |
||||||
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
||||||
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| SSEA-4 |
Yes |
|||||
| POU5F1 (OCT-4) |
Yes |
|||||
| NANOG |
Yes |
|||||
| TRA 1-60 |
Yes |
Score:
| Marker | Present | Absent |
| mCpG | ||
| OCT4 |
| Pluripotency Score | Novelty Score | |
| 19.59 | 1.42 |
Report
Pluriscore.pdf
Pluriscore
Pluritest final.jpg
Pluritest graph
Transcriptome Characterisation
Differentiation Potency
In vitro spontaneous differentiation
Morphology
Germ layer staining: AFP
Hepatocyte-like cells
Kidney organoids
Protocol or reference
Hildebrandt Reuter et al SCR 2019.pdf
Original publication
In vitro directed differentiation
Morphology
Germ layer staining: SMA
Cardiomyocytes
Protocol or reference
Hildebrandt Reuter et al SCR 2019.pdf
Original publication
In vitro spontaneous differentiation
Morphology
Germ layer staining: TUBB3
Neuron
Protocol or reference
Hildebrandt Reuter et al SCR 2019.pdf
Original publication
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
|
| Is there genome-wide genotyping or functional data available? |
Yes
|
Login to share your feedback, experiences or results with the research community.